ScinoPharm Taiwan Ltd. (TSE: 1789.TW) announced that its Tainan, Taiwan Facility provides commercial manufacturing of topiramate active pharmaceutical ingredient (“API”) for Trokendi XR™, a novel once-daily extended release formulation of topiramate for the treatment of epilepsy that was developed and recently launched by Supernus Pharmaceuticals in the U.S. market.

ScinoPharm (Changshu) Pharmaceuticals and Sundia MediTech Company Ltd. announced today a strategic alliance to seek more opportunities for collaboration on Contract Research and Manufacturing Services (CRAMS) in mainland China and to tap into this large and growing business potential.

ScinoPharm Taiwan Ltd. (TSE: 1789.TW) and Coland Holdings Ltd. (TSE: 4144.TW) announced today that they have formed a strategic alliance to develop a series of generic oncological drugs for Mainland China.

ScinoPharm (TWSE: 1789) and Foresee Pharmaceuticals, Inc. (Foresee) jointly announced today that an investment agreement to form a joint venture has been signed.

ScinoPharm (TWSE:1789) announced today that its Tainan, Taiwan Facility will provide commercial manufacturing of topiramate active pharmaceutical ingredient (“API”) for VIVUS’ Qsymia™, a new drug for the treatment of obesity approved by the United States Food and Drug Administration on July 17, 2012.